|

PD1 Inhibitors Combined With Clostridium Butyricum for Urothelial Carcinoma

RECRUITINGPhase 2Sponsored by The First Affiliated Hospital with Nanjing Medical University
Actively Recruiting
PhasePhase 2
SponsorThe First Affiliated Hospital with Nanjing Medical University
Started2024-02-01
Est. completion2029-02-01
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06696742

Summary

This study intends to explore whether the combination of Clostridium butyricum can improve the current situation of poor anti-PD1 treatment effect in patients with bladder cancer.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

For Neoadjuvant therapy:

* T2-T4aN0M0 bladder patients

For Adjuvant therapy:

* Postoperative pathological stage T3-T4 and/or lymph node metastasis were positive.

Exclusion Criteria:

* The researchers evaluated the patients who could not tolerate radical surgery;
* Previously received systemic chemotherapy or immunotherapy;
* There are active autoimmune diseases requiring systemic treatment or other diseases requiring long-term use of a large number of hormones and other immunosuppressants;
* Have had major surgery or major trauma within 28 days before joining the group;
* Vaccinated with live vaccine within 28 days before joining the group.

Conditions2

Bladder (Urothelial, Transitional Cell) CancerCancer

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.